Abstract 524P
Background
Small cell lung cancer (SCLC) has limited treatment options, especially as the number of treatment lines increases. This study investigated the standard of care (SOC) for advanced SCLC in Taiwan.
Methods
This retrospective cohort study used linked data from Taiwan Cancer Registry (TCR), National Health Insurance Research Database, and Death Registry (2014–2019). Cancer-related information was collected from TCR: age, sex, year of initial diagnosis, initial treatment status, smoking status, and genetic mutations. The algorithm for building lines of pharmacological therapies for SCLC was based on NCCN guidelines, published studies and expert opinions. Median overall survival (OS), with 95% confidence interval (CI) was estimated using the Kaplan-Meier method, referencing from the initiation of each therapy line until death or the end of 2019. Patients with documented extensive stage (ES) were analyzed in the same manner as patients with stage IV SCLC.
Results
We identified 3134 stage IV SCLC patients with a median age 69.9 years at diagnosis. Of these patients, 12% were female, and 83% were smokers. Among 2237 patients who initiated first-line (1L) therapy, 1048 (47%) patients received 2+ lines of therapy, and 349 (16%) received 3+ lines. The predominant treatments were cisplatin plus etoposide in 1L (61%) and topotecan in 2L (58%) whereas 3L treatment options included platinum plus etoposide (38%), topotecan (22%), and etoposide only (17%) regimens. Median OS with 95% CI were 8.4 (8.1–8.7) months after 1L therapy; 4.9 (4.5–5.4) months after 2L therapy, and 4.4 (3.9–5.5) months after 3L therapy. Similar characteristics and treatment regimens were observed among the 1866 patients with documented extensive-stage SCLC, with median OS of 8.6 (8.3–9.1) months after 1L therapy, 5.0 (4.5–5.6) months after 2L therapy, and 5.4 (4.3–6.2) months after 3L therapy.
Conclusions
In Taiwan, treatment regimens for advanced SCLC follow NCCN guidelines; real-world overall survival rates are consistent with published data. These results show that an urgent unmet need exists for SCLC patients. Further study is needed on immunotherapy’s effect on SCLC SOC, as our study predates insurance coverage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Amgen.
Disclosure
Y. Yang, W-J. Chen, C-H. Chang: Financial Interest, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflict of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract